Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: HIV Med. 2022 Dec 22;24(6):749–753. doi: 10.1111/hiv.13453

Table 2:

Summary of Lipid Outcomes

Pre-atorvastatin Pre-to post- atorvastatin change
Lipid Outcomes N Median 95% CI for Median Median
(Q1, Q3)
95% CI for Median
Fasting Total Cholesterol (mg/dL) 66 101.5 (96.0, 112.0) −39.0
(−58.0, −25.0)
(−46.0, −32.0)
LP-PLA2 (ng/mL) 67 135.7 (123.6, 150.9) −40.4
(−68.6, −16,4)
(−51.4, −26.0)
Oxidized LDL (u/L) 67 44.9 (41.8, 48.1) −13.8
(−18.7, −8.7)
(−15.8, −12.3)

Note: LP-PLA2: Lipoprotein-associated phospholipase A2. LDL: Low-density lipoprotein.